Mean Plasma Tofacitinib Concentration
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
04 avr. 2024 08h00 HE | Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
ABIVAX_Logo-RGB.png
Abivax reports 2023 financial results and operational update
02 avr. 2024 02h30 HE | Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
22157.jpg
Ulcerative Colitis Patient Pool Analysis, Market Size and Market Forecast in APAC Region by 2034
25 mars 2024 19h41 HE | Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034" report has been added to ResearchAndMarkets.com's offering.A...
Gastroenterologists
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
22 mars 2024 10h14 HE | Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
26 févr. 2024 08h00 HE | Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
22157.jpg
Global Ulcerative Colitis Market Projected to Reach $9.48 Billion by 2028, Driven by Telemedicine and Innovative Therapies
20 févr. 2024 04h45 HE | Research and Markets
Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The ulcerative colitis market has grown...
Stoma/Ostomy Care Market
Stoma/Ostomy Care Market to Reach US$ 4.2 Billion by 2028 Amid Rising Prevalence of IBD and Colorectal Cancer
16 févr. 2024 07h01 HE | Research and Markets
Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care Market Report by Product (Ostomy Bags, Ostomy Accessories), End User (Home Care Settings, Hospitals & Specialty Clinics), Surgery...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
15 févr. 2024 08h35 HE | Palisade Bio, Inc.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
22157.jpg
Crohn's Disease Treatment Market Set for Continued Growth, Reaching $16.32 Billion by 2028
29 janv. 2024 18h59 HE | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Crohn's Disease Treatment Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest research publication on...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
29 janv. 2024 08h05 HE | Palisade Bio, Inc.
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company...